On March 22, 2023 Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, reported that the company will present its VISTA clinical program at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2023, to be held onsite in Orlando, Florida on April 14-19, 2023 (Press release, Kineta, MAR 22, 2023, View Source;utm_medium=rss&utm_campaign=kineta-to-present-vista-biomarker-data-at-aacr-annual-meeting-2023 [SID1234629160]). Thierry Guillaudeux, Ph.D., Chief Scientific Officer of Kineta, will give a poster presentation highlighting new preclinical data on VISTA expression as a potential biomarker in patients with advanced solid tumors.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentation Details:
Poster Title: VISTA expression in patients with advanced solid tumors: A potential biomarker in VISTA-101 clinical trial
Abstract Number: 972
Session Title: Biomarkers of Therapeutic Benefit 1
Session Date and Time: Sunday, April 16, 2023 at 1:30 P.M. – 5:00 P.M. Eastern Time
Location: Section 39